• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>High Altitude Medicine Biology >Oral Coenzyme Q10 Supplementation Does Not Prevent Cardiac Alterations During a High Altitude Trek to Everest Base Camp
【2h】

Oral Coenzyme Q10 Supplementation Does Not Prevent Cardiac Alterations During a High Altitude Trek to Everest Base Camp

机译：口服辅酶Q10补充剂无法阻止在珠穆朗玛峰大本营高空跋涉期间发生心脏改变

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

Holloway, Cameron J., Andrew J. Murray, Kay Mitchell, Daniel S. Martin, Andrew W. Johnson, Lowri E. Cochlin, Ion Codreanu, Sundeep Dhillon, George W. Rodway, Tom Ashmore, Denny Z.H. Levett, Stefan Neubauer, Hugh E. Montgomery, Michael P.W. Grocott, and Kieran Clarke, on behalf of the Caudwell Xtreme Everest 2009 Investigators. Oral Coenzyme Q supplementation does not prevent cardiac alterations during a high altitude trek to Everest Base Camp. High Alt Med Biol 15:000—000, 2014.—Exposure to high altitude is associated with sustained, but reversible, changes in cardiac mass, diastolic function, and high-energy phosphate metabolism. Whilst the underlying mechanisms remain elusive, tissue hypoxia increases generation of reactive oxygen species (ROS), which can stabilize hypoxia-inducible factor (HIF) transcription factors, bringing about transcriptional changes that suppress oxidative phosphorylation and activate autophagy. We therefore investigated whether oral supplementation with an antioxidant, Coenzyme Q10, prevented the cardiac perturbations associated with altitude exposure. Twenty-three volunteers (10 male, 13 female, 46±3 years) were recruited from the 2009 Caudwell Xtreme Everest Research Treks and studied before, and within 48 h of return from, a 17-day trek to Everest Base Camp, with subjects receiving either no intervention (controls) or 300 mg Coenzyme Q10 per day throughout altitude exposure. Cardiac magnetic resonance imaging and echocardiography were used to assess cardiac morphology and function. Following altitude exposure, body mass fell by 3 kg in all subjects (p<0.001), associated with a loss of body fat and a fall in BMI. Post-trek, left ventricular mass had decreased by 11% in controls (p<0.05) and by 16% in Coenzyme Q10-treated subjects (p<0.001), whereas mitral inflow E/A had decreased by 18% in controls (p<0.05) and by 21% in Coenzyme Q10-treated subjects (p<0.05). Coenzyme Q10 supplementation did not, therefore, prevent the loss of left ventricular mass or change in diastolic function that occurred following a trek to Everest Base Camp.
机译：Holloway，Cameron J.，Andrew J.Murray，Kay Mitchell，Daniel S.Martin，Andrew W.Johnson，Lowri E.Cochlin，Ion Codreanu，Sundeep Dhillon，George W.Rodway，Tom Ashmore，Denny Z.H.莱维特，斯特凡·纽鲍尔，休·蒙哥马利，迈克尔·P·W Grocott和Kieran Clarke代表Caudwell Xtreme Everest 2009调查员。口服辅酶Q补充剂不能防止在珠穆朗玛峰大本营的高海拔跋涉期间发生心脏改变。 High Alt Med Biol 15：000-000，2014年。—暴露于高海拔地区与持续但可逆的心脏质量，舒张功能和高能磷酸盐代谢有关。尽管基本机制仍然难以捉摸，但组织缺氧会增加活性氧（ROS）的生成，从而可以稳定低氧诱导因子（HIF）转录因子，从而产生抑制氧化磷酸化并激活自噬的转录变化。因此，我们研究了口服补充抗氧化剂辅酶Q10是否能防止与海拔高度暴露相关的心脏摄动。从2009年Caudwell Xtreme Everest Research Treks招募了23名志愿者（10名男性，13名女性，46±3岁），在返回珠穆朗玛峰大本营之前和之后的48小时内进行了研究，受试者包括受试者在整个高度暴露期间，每天不接受干预（对照）或每天服用300μmg辅酶Q10。心脏磁共振成像和超声心动图用于评估心脏的形态和功能。在海拔高度暴露后，所有受试者的体重下降3 kg（p <0.001），这与体脂减少和BMI下降有关。跋涉后，左室重量在对照组中下降了11％（p <0.05），在辅酶Q10治疗的受试者中下降了16％（p <0.001），而二尖瓣流入量E / A在对照组中下降了18％（p <0.05）和辅酶Q10治疗的受试者中21％（p <0.05）。因此，补充辅酶Q10并不能防止迷路到珠穆朗玛峰大本营后发生的左心室质量损失或舒张功能改变。

著录项

相似文献

  • 外文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号